| Α   | В                              | С                            | D                            | E                            |
|---|--------------------------------|------------------------------|------------------------------|------------------------------|
| RowLabel                                    | 62559027583                    | 62559027671                  | 62559027705                  | 62559027805                  |
| NDC11                                       | 62559027583                    | 62559027671                  | 62559027705                  | 62559027805                  |
| Trade Name                                  | Nebivolol Tablets 2.5mg 2300ct | Nebivolol Tablets 5mg 1100ct | Nebivolol Tablets 10mg 500ct | Nebivolol Tablets 20mg 500ct |
| Chemical Name                               | Nebivolol                      | Nebivolol                    | Nebivolol                    | Nebivolol                    |
| Product introduction date                   | 10/01/2021                     | 10/01/2021                   | 10/01/2021                   | 10/01/2021                   |
| Wholesale Acquisition Cost (WAC) per        |                                |                              |                              |                              |
| package                                     | \$6,478.33                     | \$3,098.33                   | \$1,408.33                   | \$1,408.33                   |
| Wholesale Acquisition Cost (WAC) per        |                                |                              |                              |                              |
| treatment course                            | \$6,478.33                     | \$3,098.33                   | \$1,408.33                   | \$1,408.33                   |
| Description of the marketing and pricing    |                                |                              |                              |                              |
| plans used in the launch of the new drug in |                                |                              |                              |                              |
| the United States and internationally       |                                |                              |                              |                              |
| Estimated volume of patients who may be     |                                |                              |                              |                              |
| prescribed the drug                         |                                |                              |                              |                              |
| Granted breakthrough therapy designation    |                                |                              |                              |                              |
| or priority review by the FDA?              | No                             | No                           | No                           | No                           |
| Date of acquisition (if acquired)           |                                |                              |                              |                              |
| Price of acquisition (if acquired)          |                                |                              |                              |                              |
|   |                                |                              |                              |                              |